<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We present a case report of a 55-year-old male patient with hypoplastic <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:hpo ids='HP_0005505'>refractory anemia</z:hpo>) in which a good response to recombinant human erythropoietin (rhEPO) has been maintained for more than 60 months </plain></SENT>
<SENT sid="1" pm="."><plain>There is with no evidence of progression to high risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, although he was predicted to be a low-responder to rhEPO therapy because of very high serum EPO levels (5,260 mU/ml), a history of multiple transfusions, chromosomal abnormalities (47,XY,+8) and severe <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Since he received rhEPO with no adverse effects, it may be valuable to try rhEPO treatment at least one time for low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, depending on red cell transfusion requirements </plain></SENT>
</text></document>